Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II trial of Nepafenac Evolute shows postoperative pain reduction after cataract surgery

May 8, 2019

MaxCyte advances phase I trial of MCY-M11 in advanced ovarian cancer and peritoneal mesothelioma

May 8, 2019

REGENXBIO offers new interim phase I/IIa data on RGX-314 in wet AMD

May 8, 2019

Durect reports preliminary data from phase IIa study of DUR-928 in alcoholic hepatitis

May 8, 2019

JS Innopharm patents IDO1 and/or TDO inhibitors

May 8, 2019

Jubilant Biosys describes new PADI4 inhibitors

May 8, 2019

Enterprise Therapeutics discloses SCNN1A blockers

May 8, 2019

Japanese researchers present IDO1 and/or TDO inhibitors

May 8, 2019

Merck & Co. patents LRKK2-mutant inhibitors

May 8, 2019

Pilot study of L1-79 demonstrates trends towards improvement in male subjects with ASD

May 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...